NCT07760662Recruiting

Oxidative Stress and Cardiovascular Risk in Patients With Rheumatoid Arthritis

Oxidative Stress and Cardiovascular Comorbidity in Patients With Rheumatoid Arthritis

Source: ClinicalTrials.gov · Last updated 12 Aug 2026

Brief summary (registry, in English)

The pathogenic process underlying atherosclerosis resembles a chronic inflammatory response in which oxidative stress is involved. Similarly, oxidative stress is widely recognized to play an important role in the clinical course and pathogenesis of rheumatoid arthritis (RA). RA has been associated with accelerated atherosclerosis. This cross-sectional study will include patients with RA. The primary objective is to evaluate the association between selected oxidative stress biomarkers-serum malondialdehyde levels, superoxide dismutase, and glutathione peroxidase-and the presence of subclinical atherosclerosis and carotid arterial stiffness in patients with RA. We will subsequently assess whether these molecules are related to cardiovascular disease determinants, including inflammatory dyslipidemia, insulin resistance, and beta-cell dysfunction, which may occur in this condition. This study will further explore the relationship between oxidative stress and cardiovascular disease in RA.

Status (registry): Recruiting
Study type: Observational
Enrollment: 200 (estimated)
First submitted: 7 Aug 2026
Start date: 1 Jan 2024
Primary completion date: 1 Aug 2026
Lead sponsor: University of La Laguna
Diseases: Rheumatoid arthritis
NCT number: NCT07760662

What you commit to

Study type: Observational
Planned participants: 200
From 1 Jan 2024 to the primary completion date, 1 Aug 2026
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

Evidence of severe uncontrolled concomitant cardiovascular, neurological, pulmonary (including obstructive lung disease), renal, hepatic, endocrine (including diabetes mellitus), or gastrointestinal disease, or any condition considered by the investigator likely to alter the lipid profile.
History of alcoholism, drug abuse, or substance misuse within six months before the screening visit.

Other illness

Autoimmune rheumatic disease other than RA, including systemic lupus erythematosus, mixed connective tissue disease, systemic sclerosis, or polymyositis. Sjögren syndrome associated with RA will not be an exclusion criterion.
History or current presence of inflammatory joint disease other than RA, such as gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, or Lyme disease.
Estimated glomerular filtration rate below 60 mL/min/1.73 m² or active renal disease.

Other

Functional class IV RA with complete or substantial disability, including confinement to bed or wheelchair that prevents personal self-care.
Pregnancy or breastfeeding.
Body weight greater than 150 kg.
Statin use will not be an exclusion criterion.

Who the study is looking for

Men or women who are not pregnant or breastfeeding.
Age 18 years or older and younger than 70 years.
Treatment with any disease-modifying antirheumatic drug, including biologic therapies.
For patients receiving oral corticosteroids, a prednisone dose of 10 mg or less that has remained stable for at least one month before study inclusion.
Ability and willingness to provide written informed consent.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
Hospital Universitario de Canarias Coordinator of this site? Confirm its status	Santa Cruz de Tenerife	Spain	Recruiting

This page is information, not medical advice. Discuss any trial with your doctor.